Based on the latter observation, preclinical models have unveiled that PARPi upregulates PD-L1 expression primarily through GSK3β inactivation in a dose-dependent manner, suppressing T-cell activation and increasing tumor cell killing [76]. The gene discussed is CD274; the disease is neoplasm.